Antimicrobial susceptibility of Shigella isolates in eight Asian countries, 2001-2004

Journal of Microbiology, Immunology and Infection

Volumn 41, Issue 2, 2008, Pages 107-111

  Kuo, Chen Yen ^a   Su, Lin Hui ^a   Perera, Jennifer ^b   Carlos, Celia ^c   Tan, Ban Hock ^d   Kumarasinghe, Gamini ^d   So, Thomas ^e   Van, Pham Hung ^f   Chongthaleong, Anan ^g   Song, Jae Hoon ^h   Chiu, Cheng Hsun ^a,i  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b UNIVERSITY OF COLOMBO   (Sri Lanka)

^c RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e PRINCESS MARGARET HOSPITAL   (Hong Kong)

^f UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY   (Viet Nam)

^g CHULALONGKORN UNIVERSITY   (Thailand)

^h Samsung Medical Center   (South Korea)

ⁱ CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

Author keywords

Asia; Microbial sensitivity tests; Shigella

Indexed keywords

AMPICILLIN; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD GROUP TYPING; HEALTH CENTER; NONHUMAN; SHIGELLA; SHIGELLA FLEXNERI; SHIGELLA SONNEI;

ANTI-BACTERIAL AGENTS; ASIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DYSENTERY, BACILLARY; HUMANS; MICROBIAL SENSITIVITY TESTS; SEROTYPING; SHIGELLA;

EID: 48649089208     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Salam MA, Bennish ML. Antimicrobial therapy for shigellosis. Rev Infect Dis. 1991;13(Suppl 4):S332-41.
2. Bhattacharya SK, Sur D. An evaluation of current shigellosis treatment. Expert Opin Pharmacother. 2003;4:1315-20.
3. Tong MJ, Martin DG, Cunningham JJ, Gunning JJ. Clinical and bacteriological evaluation of antibiotic treatment in shigellosis. JAMA. 1970;214:1841-4.
4. Oh JY, Yu HS, Kim SK, Seol SY, Cho DT, Lee JC. Changes in patterns of antimicrobial susceptibility and integron carriage among Shigella sonnei isolates from southwestern Korea during epidemic periods. J Clin Microbiol. 2003; 41:421-3.
5. Isenbarger DW, Hoge CW, Srijan A, Pitarangsi C, Vithayasai N, Bodhidatta L, et al. Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999. Emerg Infect Dis. 2002;8:175-80.
6. Replogle ML, Fleming DW, Cieslak PR. Emergence of antimicrobial-resistant shigellosis in Oregon. Clin Infect Dis. 2000;30:515-9.
7. Gaudreau C, Turgeon P. Antibiotic resistance of Shigella spp., Salmonella spp., and Yersinia spp. isolated in Quebec. Can Commun Dis Rep. 1997;23:57-9.
8. Maraki S, Georgiladakis A, Christidou A, Scoulica E, Tselentis Y. Antimicrobial susceptibilities and beta-lactamase production of Shigella isolates in Crete, Greece, during the period 1991-1995. APMIS. 1998;106:879-83.
9. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial disk susceptibility tests: Approved standard. NCCLS document M2-A7. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000.
10. Ashkenazi S, May-Zahav M, Dinari G, Gabbay U, Zilberberg R, Samra Z. Recent trends in the epidemiology of Shigella species in Israel. Clin Infect Dis. 1993;17: 897-9.
11. Chuang YY, Huang YC, Lin SY. Outbreak of Shigella sonnei gastroenteritis in Northeastern Taiwan. Pediatr Infect Dis J. 2006;25:92-4.
12. Department of Health, Taiwan, R.O.C. Statistically important characteristics in public health in Taiwan, Republic of China. Taipei, Taiwan: Republic of China Department of Health; 2002.
13. Ashkenazi S, Levy I, Kazaronovski V, Samra Z. Growing antimicrobial resistance of Shigella isolates. J Antimicrob Chemother. 2003;51:427-9.
14. Sivapalasingam S, Nelson JM, Joyce K, Hoekstra M, Angulo FJ, Mintz ED. High prevalence of antimicrobial resistance among Shigella isolates in the United States tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002. Antimicrob Agents Chemother. 2006;50:49-54.
15. von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med. 2006;3:e53.
16. World Health Organization. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. Geneva, Switzerland: World Health Organization, 2005. Available from: http://www.who.int/vaccine_research/ documents/Guidelines_Shigellosis.pdf
17. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis J. 1997;16:127-9.
18. Jick S. Ciprofloxacin safety in a pediatric population. Pediatr Infect Dis J. 1997;16:130-3.
19. Bhattacharya K, Bhattacharya MK, Dutta D, Dutta S, Deb M, Deb A, et al. Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta Paediatr. 1997;86:319-20.
20. Green S, Tillotson G. Use of ciprofloxacin in developing countries. Pediatr Infect Dis J. 1997;16:150-9.